Compare the Hemoglobin and Hematocrit Variability Between Once & Three Times Weekly Erythropoietin Therapy for the Anemia in Patients With Maintenance Dialysis

NCT01111630 Phase 4 COMPLETED

The purpose of this study is to compare the hemoglobin and hematocrit variability between once and three times weekly erythropoietin therapy for the anemia in patients with maintenance dialysis.

Details

Lead sponsor	JW Pharmaceutical
Phase	Phase 4
Status	COMPLETED
Enrolment	60
Start date	2009-10
Completion	2014-01

Conditions

• Chronic Renal Failure
• Anaemia

Interventions

• recomon (Epoetin Beta)
• recomon (Epoetin Beta)

Primary outcomes

• The hemoglobin variability between once & three times weekly administration — 24 weeks

Countries

South Korea